Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.
Subscribe to our email newsletter
The study, published in the journal Cancer, reveals that combination therapy showed the greatest benefit for HIV patients suffering from aggressive malignant non-Hodgkin’s lymphoma. This benefit was most pronounced in HIV patients without severely impaired immune functions. These so-called “standard risk” patients responded as well to therapy and survived as long as lymphoma patients without HIV.
Lymphomas are cancers of the immune system’s white blood cells. They are treated with chemotherapy, often consisting of a multi-drug regimen using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). People with HIV are at increased risk of developing lymphomas, particularly aggressive, fast-growing non-Hodgkin type lymphomas. These are called AIDS-related lymphomas (ARL) and generally have a poorer prognosis than non-HIV-related lymphomas.
Highly active antiretroviral therapy (HAART) revolutionized care of HIV-positive men and women. It not only improves laboratory indicators, such as increased CD-4 cells and reduced viral loads, but also significantly improves survival and delays the onset of AIDS and AIDS-related cancers, including lymphomas.
With the lack of study data to show the efficacy of maintaining HIV-positive patients on HAART while they are treated with chemotherapy for ARL, oncologists are hesitant to expose HIV patients to hypothetical drug toxicities related to combining the therapies.
Researchers led by Dr Rudolf Weiss, of Specialist Practice for Hematology, Oncology and Infectious Diseases in Bremen, Germany, treated 72 HIV-patients with ARL divided into high-risk and standard-risk cohorts with combined CHOP and HAART to evaluate the safety and efficacy of the combined regimen.
The investigators found combined therapy improved survival rates for patients with ARL and standard level of risk to rates comparable to those in non-HIV patients with lymphoma treated with CHOP and superior to previously published rates achieved by CHOP alone.
For standard-risk ARL patients, 79% achieved complete remission, and after 47 months of follow-up and study’s end, more than 50% of patients survived. Moreover, only 40% reported moderate drug toxicity.
For high-risk ARL patients, only 29% achieved complete remission and median survival was only 7.2 months. In terms of adverse event data, 69% reported moderate toxicity.